Hot Pursuit     10-Apr-23
Zydus Life gets USFDA nod for Azithromycin tablets
Zydus Lifesciences said that it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Azithromycin Tablets USP, 500 mg.
The said drug is equivalent to reference listed drug, Zithromax tablets. Azithromycin is indicated to treat certain bacterial infections such as bronchitis, pneumonia, sexually transmitted diseases (STD), infections of the ears, lungs, sinuses, skin, throat, and reproductive organs.

The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).

Azithromycin tablets USP, 500 mg had annual sales of $20 million in the United States (IQVIA MAT February. 2023).

As on 31 December 2022, the group has 360 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit jumped 24.5% to Rs 622.90 crore on 17.9% rise in net sales to Rs 4,159.80 crore in Q3 FY23 over Q3 FY22.

The scrip rose 0.50% to Rs 496.45 on the BSE.

Previous News
  Indices trade near flat line; Media shares rally
 ( Market Commentary - Mid-Session 18-May-24   10:32 )
  Volumes spurt at Zydus Lifesciences Ltd counter
 ( Hot Pursuit - 18-Dec-23   11:00 )
  Zydus Life gains on USFDA nod for phase 2 clinical trial of ZYIL1
 ( Hot Pursuit - 18-Dec-23   09:22 )
  Zydus receives WHO approval for the name ‘Usnoflast' for ZYIL1
 ( Corporate News - 01-Apr-24   20:34 )
  Zydus Lifesciences Ltd Slides 1.88%
 ( Hot Pursuit - 18-Jun-24   09:30 )
  Zydus Life commences phase IV trial for fatty liver disease drug
 ( Hot Pursuit - 09-Jun-23   10:26 )
  Zydus commences phase IV EVIDENCES- XI trial for Saroglitazar Mg
 ( Corporate News - 09-Jun-23   10:03 )
  Zydus Life gets US FDA nod for seizure treatment drug Lacosamide
 ( Hot Pursuit - 16-Dec-23   15:37 )
  Zydus Lifesciences Ltd spurts 1.42%, up for third straight session
 ( Hot Pursuit - 07-Aug-23   13:05 )
  Zydus Lifesciences receives USFDA approval for Lacosamide Tablets
 ( Corporate News - 16-Dec-23   11:43 )
  Zydus launches Topiramate Extended-Release Capsules
 ( Corporate News - 06-Jan-23   13:20 )
Other Stories
  Dhanlaxmi Bank gains as gross advances rises 6% YoY in Q1 FY25
  05-Jul-24   15:27
  HDFC Bank Ltd leads losers in 'A' group
  05-Jul-24   15:00
  Shilpa Medicare sizzles after Unicycive gets positive results in clinical trials of OLC
  05-Jul-24   14:52
  Manugraph India Ltd leads losers in 'B' group
  05-Jul-24   14:45
  NSE SME Nephro Care India rallies on listing day
  05-Jul-24   14:45
  ESAF SFB total deposits jumps 33% YoY in Q1
  05-Jul-24   14:43
  Utkarsh SFB deposits climb 30% YoY in Q1 FY25
  05-Jul-24   14:35
  Volumes soar at Medplus Health Services Ltd counter
  05-Jul-24   14:30
  Financials stocks slide
  05-Jul-24   14:00
  Banking stocks edge lower
  05-Jul-24   14:00
Back Top